The IMID Forum

Prof Vibeke Strand from Stanford University. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Vibeke Strand discusses improvements in patient-reported outcomes with upadacitinib.

Iain McInnes discusses patient-reported outcomes. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Member of the US Centers for Disease Control and a co-author of more than 100 publications. In this podcast, Prof Kevin Winthrop discusses the impact concomitant treatments have on HZ risk with Professor Maurizio Cutolo from the University of Genova. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.

Professor McInnes presents the most notable papers of 2019. You can find detailed summaries of the papers highlighted on http://www.cytokinesignalling.com/en/publications/review-article/511/

Professor McInnes presents the monthly podcast reviewing a paper by Professor Ying‐Chou Chen and another paper by Professor Genovese.

Professor McInnes presents the monthly podcast reviewing a paper by Dr Katie Bechman and another paper by Professor Lee YH.

In this edition of Congress Author Podcasts, recorded at ACR 2019, the latest data from the FINCH studies are presented by Professors Taylor, Westhovens and Winthrop, in addition to filgotinib safety data from a phase 2 Psoriatic Arthritis trial, presented by Professor Coates.

In this edition, recorded at ACR 2019, real-world tofacitinib safety data is presented by Professor Kremer and the impact of baricitinib and tofacitinib on pain is analysed by Professors Taylor and Dougados

In this edition experts, including Professor Smolen and Professor McInnes, present the latest data for the recently approved JAK inhibitor, upadacitinib. The presentations include: data from the SELECT trials, safety analyses, switching from TNF inhibitors, and the mode of action of upadacitinib.

Professor Calabrese introduces highlights from Day 4 of ACR 2019